MedTrace Logo

Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity

NCT07070765 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-04-30

No results posted yet for this study

Summary

Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.

Conditions

Interventions

DRUG

Sodium-glucose transport-2 (SGLT-2) inhibitors

Dapagliflozin 10mg in addition to standard clinical care

OTHER

Standard medical treatment

Standard clinical care

Sponsors & Collaborators

  • NHS Grampian

    collaborator OTHER_GOV

  • University of Aberdeen

    lead OTHER

Principal Investigators

  • Dana Dawson, MPhil · University of Aberdeen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-12
Primary Completion
2028-10-31
Completion
2028-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07070765 on ClinicalTrials.gov